VF
BTAI icon

Virtu Financial’s BioXcel Therapeutics BTAI Stock Holding History

Virtu Financial’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,666
Closed -$22K – 1495
2025
Q1 		$22K Buy
10,666
+9,605
+905% +$35.9K ﹤0.01% 1092
2024
Q4 		$6K Buy
+1,061
New +$8.86K ﹤0.01% 1421
2024
Q3 		– Sell
-3,584
Closed -$73K – 1407
2024
Q2 		$73K Buy
3,584
+2,710
+310% +$90.7K 0.01% 862
2024
Q1 		$39K Sell
874
-2,846
-77% -$136K ﹤0.01% 1059
2023
Q4 		$176K Buy
+3,720
New +$207K 0.01% 880
2022
Q1 		– Sell
-768
Closed -$250K – 1528
2021
Q4 		$250K Buy
+768
New +$330K 0.03% 728

Other funds holding BTAI

OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.98B AUM 29.21% 1-Year Est. Return
OFA
Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Virtu Financial's BTAI Position: Q2 2025 in Review

Virtu Financial sold out of BioXcel Therapeutics (BTAI) in Q2 2025, closing a stake of 10,666 shares — an estimated $22K sold.

Virtu Financial first reported a position in BTAI in Q4 2021 and held it in 6 quarters. The position peaked at $250K in Q4 2021. 35 funds tracked by Wall St. Rank hold BTAI as of Q2 2025.

  • Virtu Financial reported no remaining BioXcel Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Virtu Financial sold 10,666 BioXcel Therapeutics shares in Q2 2025, an estimated $22K.
  • Virtu Financial first reported a position in BioXcel Therapeutics in Q4 2021 and held it in 6 quarters.
  • Virtu Financial's BioXcel Therapeutics position peaked at $250K in Q4 2021.
  • 35 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2025.

Based on Virtu Financial's 13F filing for Q2 2025, filed 12 Aug 2025.